Kenneth

“Goldman Sachs to pay $500 million to settle shareholder lawsuit over 1MDB scandal” “Goldman Sachs has agreed to pay $500 million to settle a class action lawsuit accusing the Wall Street bank of defrauding shareholders about its work for 1MDB, a Malaysian sovereign wealth ‌fund that became embroiled in a corruption scandal……. U.S. and Malaysian authorities have said $4.5 billion was siphoned away from 1MDB, with some diverted to offshore ‌bank ⁠accounts and shell companies linked to Low. Goldman helped 1MDB sell $6.5 billion of bonds and collected an estimated $600 million in fees. Shareholders accused the bank of lying about its role in the fraud while repeatedly touting its supposedly robust risk management…

I wrote an article about $NWBO: reddit.com/r/NWBO/comment… I encourage everyone to read it. What is happening with NWBO is astounding and our persistent retail investor has hung on through it all. I believe we will all be much better off when this story comes to its' ending.

NWBO '26 Q1 10Q #Item1LegalProceedings_666834" target="_blank" rel="nofollow noopener">sec.gov/ix?doc=/Archiv… At this point I’m skimming the filings for information regarding $NWBO's commercialization of their lead product and steps $NWBO might take to address their cash crunch. The information on additional trials and US manufacturing is great, but those trials and US manufacturing are many many years away from positively impacting the finances. Here is what stood out to me in $NWBO's recent '26 Q1 10Q. ➡️Significant Reduction in Net Loss The net loss for the 3 months ended March 31st from 2025 was $19.343m and for 2026 it was reduced to $3.069m. I’d imagine we are starting to feel the Advent merger synergies. ➡️Another Approval Timeline Hint First, lets look my at the prior speculation on timelines. Speculation #1: Per data posted by Tunnelvisionplenty, there is a big batch of approvals coming 6 months post the 2nd CHM meeting. $NWBO had their 2nd CHM meeting on November 27/28 of 2025. Six months past this date is late May 2026. Speculation #2: For the first time in the ’25 10k we saw that Advent started DCVax-L specific training which typically takes about six months. I assume they wanted this training to be complete prior to approval. This statement wasn’t in the ’25 Q3 10Q. So, this training likely started October-December ’25 timeframe. That means the training would be complete in the April-June ’26 timeframe. Speculation #3 (contained in recent 10Q): In this ’26 Q1 10Q we see that $NWBO started a leukapheresis buildout in the UK. I assume this is being timed to be done for the approval decision. The 10Q states that $NWBO expects the buildout “…to be completed by June…” So, we have three separate signals pointing to approval in May, April-June and finally June. There is an ongoing CHM meeting for May 21/22. Hopefully $NWBO is on the agenda at this CHM and we have an approval decision in mid ’26 as a few speculative timelines are starting to align. ➡️Potential UK Property Sale "The Company owns a 17-acre parcel of land on the edge of Sawston, UK...If zoned for residential development, the Company has been advised that its property would be extremely valuable." This is a positive step to possibly address $NWBO’s cash crunch and something to keep an eye on. I would also like to know what the company means by "extremely valuable". ➡️Spoofing Lawsuit Settlement Language “The funds are being held in escrow while the Company pursues discussions with other lesser defendants about resolution of the case against them. The Company anticipates that the funds will be released from escrow when the discussions with the lesser defendants have been completed.” That’s a positive sign that some of the smaller players are possibly talking settlement. I’m surprised $NWBO put this language in a public filing. Regarding the statement that the funds will remain in escrow until discussions with lesser defendants have been completed is puzzling. I’m not sure why those funds would be required to stay in escrow until discussions with other parties are complete. The only thing I can think of with my limited knowledge of the situation is that $NWBO sold interest in the lawsuit to certain investors and maybe their agreement stated that the first [insert dollar value] of the settlement goes to paying off the investors. Maybe $NWBO is required to hold the funds in escrow until the settlement has reached a certain amount to pay off the initial investment of the investors. Who knows. It's an unusual statement so I figure it has something to do with the possible unusual arrangement of selling lawsuit interests to investors. That's all that stood out to me on the commercialization/cash front. Fingers crossed for mid '26 approval decision!

$NWBO PhalanxWarrior shared an idea on Stocktwits stocktwits.com/PhalanxWarrior…

$NWBO Laura Posner is the Lead Counsel for Northwest Biotherapeutics vs Citadel She is also… “✅Former Bureau Chief of the New Jersey Bureau of Securities: literally the state’s Top Securities Regulator & ENFORCER. ..” - @EatYerShorts June 2024 "The case is still in its early stages, but for context it’s a classic good guy vs. bad guy story." - that 2023 quote is from Laura Posner, x.com/kshaughnessy2/…

🧑‍⚖️Two Rulings, Two (mostly) wins for $NWBO The Case: Northwest Biotherapeutics, Inc v. Canaccord Genuity LLC, 1:22-cv-10185, (S.D.N.Y.) The Docket: courtlistener.com/docket/6657959… Keep in mind these are discovery rulings. That being said, these were two important wins for $NWBO in their spoofing lawsuit against seven of the largest market makers in the world. ✅May 19, 2026 Ruling The 'I don't care to read the below quotes summary': This ruling stops the Defendants from getting a sneak peak at $NWBO's underlying analysis and protects Joshua Mitts from having to produce a burdensome document by document privilege log. "...the Court hereby GRANTS the motion for a protective order to the extent indicated below." "The Court is unpersuaded by Citadel’s argument that NWBO waived Rule 26(b)(4)(D) protections because statistical analyses prepared by Professor Mitts were incorporated into the Second Amended Complaint (“SAC”)." "The Court also finds that a detailed privilege log is unwarranted to the extent the documents sought are protected by Rule 26(b)(4)(D)." "Although the Court thus finds that Rule 26(b)(4)(D) shields Mitts from providing documents concerning his work as a non-testifying consulting expert, it is not clear that this relieves him of any obligation to comply with the subpoena." "Citadel, however, states that it would be willing to accept a categorical privilege log, and the Court agrees that a categorical log, with information as to date range, general subject matter, and the privilege(s) asserted, would be appropriate." ✅May 20, 2026 Ruling The tldr summary: The Court is granting $NWBO's request for a discovery continuance but they're annoyed at the slow pace of discovery so the Court is taking steps to speed things up. "Having reviewed this letter, Defendants’ response (Dkt. No. 274), and the parties’ May 4, 2026 status report (Dkt. No. 270), the Court is not satisfied with the progress of discovery in this case. The original Scheduling Order, entered following the Initial Case Management Conference held on June 5, 2025, set a deadline for substantial completion of document production of August 29, 2025. (Dkt. No. 218 at 3). This date was mutually agreed to, and indeed proposed by, the parties. (Dkt. No. 205 at 7). Yet eleven months after the ICMC, and with the extended deadline for substantial completion of document discovery just two weeks away (Dkt. No. 254), Plaintiff writes that “the parties have yet to agree on search terms for either NWBO or Defendants.” (Dkt. No. 269 at 1 n.2; emphasis added). The Court does not understand how that could possibly be the case if the parties were working diligently, cooperatively, and in good faith to complete discovery in the allotted time. Nor does the Court understand how, after eleven months of discovery, so few documents have been produced in a case of this nature. To the extent there is any bona fide issue relating to search terms (the Court recognizes that Defendants say they understood that the search terms, at least for their own production, were already agreed to and that they produced documents based on that understanding, see Dkt. No. 274 at 2)), it must be resolved immediately. Similarly, any dispute as to Defendants’ production of trading data, described in the parties’ exchange of letters in November 2025 (see Dkt. No. 274 Exs. B and C), must be resolved immediately. The parties shall meet and confer and, by no later than next Friday, May 29, 2026, file a joint status letter that either (a) reports that these issues have been resolved (for both NWBO’s and Defendants’ productions) and provides a revised deadline for substantial completion of document production no later than July 31, 2026; or (b) states that the Court’s intervention is needed and provides each party’s position in no more than 3 pages for each side. To facilitate discussions regarding search terms, Plaintiff shall provide Defendants with string-by-string hit counts (and not just an aggregate hit count), or forfeit any ability to argue that Defendants’ proposed search terms are unduly burdensome. Pending receipt of the parties’ May 29 letter, the Court holds in abeyance NWBO’s request for an extension of discovery deadlines. SO ORDERED."

$NWBO New Dockets NWBO Requests Extension on Discovery and Judge has signed off. "Pending receipt of the parties’ May 29 letter, the Court holds in abeyance NWBO’s request for an extension of discovery deadlines" Judge seems pissed on several fronts , see page 4...

$NWBO 4 Gen 💰 💰 Marching FORWARD in $SPOOFING Weeks ago a Citadel attorney resigned! NOW: Judge quashed Citadel motions: investorshub.advfn.com/boards/read_ms… Thanks to @EatYerShorts

Have the MMs and spoofing algos finally met their worst frickin' nightmare? Meet Professor Joshua Mitts, the Columbia Law data science weapon #NWBO just shielded from Citadel’s desperate subpoena. This ain't some academic in an ivory tower. He’s the short sellers’ personal hell. Thread 👇

BIG courtroom win for $NWBO The judge “quashed Citadel’s aggressive subpoena on Professor Joshua Mitts.” Who is Joshua Mitts? “The short sellers’ personal hell… …Mitts is the godfather of exposing “Short and Distort” schemes. He’s published brutal empirical takedowns on spoofing, layering, pseudonymous attacks, and manipulative options trading that create fake sell pressure. He turns trading data into smoking guns. 👇 ..” -@EatYerShorts

$NWBO 1.38 million share buy at 1:09 pm today. Gobble gobble.

The entire ATMP sector in the UK is focused on one question: how do we move advanced therapies from bespoke experimental treatments into repeatable clinical reality? $NWBO was a sponsor & organizer of the KHP’s Advanced Therapies Conference alongside AstraZeneca and Gilead.

📣📣 NWBO PRESENTED ENOUGH PLAUSIBLE CLAIMS FOR DISCOVERY Citadel Securities denying the claims as frivolous but the Judge doesn't see it that way. Canaccord Genuity has settled the portion of the claim. Exposure is growing and Judges are starting to ask for discovery. MMAT MMTLP Bankruptcy case is another shining example of that.

$NWBO Linda Powers was always ahead of her time. 😎👇🏽 youtu.be/MJzoBQVOGWs?si…

$NWBO More Details On An Expensive 2026 for Canaccord - because they didn’t play fair. And a warning to other broker dealers. A recap - Canaccord agrees to $120 Million settlement with regulators because Canaccord ignored money laundering red flags in penny stock trades for over 10 years. Then weeks later, the broker quietly settled Northwest Bio’s ($NWBO) spoofing lawsuit. “The substance of the enforcement action is damning by any measure. Canaccord admitted willfully violating the Bank Secrecy Act on three core fronts:….. …..The firm was heavily involved in low-priced equity transactions across over-the-counter markets, an environment historically associated with elevated fraud risk including pump-and-dump schemes and market manipulation…”

Since $NWBO has disclosed settlement from market makers, it's time to establish share buyback program. These funds should not be used for R&D or G&A. They were paid to redress direct shareholder harm. Return shareholder capital as without it this company would be bankrupt.

$NWBO Submission to the FDA in Q2 2026!!!

Here is highlights having AI read the 10-Q Note : I am still proof reading, so FYI $NWBO NWBO reported $494,000 in revenue, $11.4 million in operating costs, and a net loss of $3.1 million for Q1 2026, compared with a $19.3 million net loss in Q1 2025. The smaller loss was not mainly from commercial revenue; it was helped by a $2.25 million Delaware litigation settlement gain, a $9.4 million non-cash fair-value derivative gain, and a $5.2 million non-cash fair-value gain on convertible notes. Share count / dilution The cover page says that as of May 13, 2026, NWBO had 1,643,343,757 common shares outstanding. On the balance sheet, it shows 1,606.9 million shares outstanding as of March 31, 2026 and 1,555.4 million as of December 31, 2025. So, roughly speaking, the common share count rose about 51.5 million during Q1, then another ~36.4 million after quarter-end through May 13, based on the rounded March 31 figure. NWBO raised $2.9 million from common share issuance and $7.5 million from convertible notes during Q1 2026. It also converted about $8.9 million of debt and accrued interest into common stock, based on the stockholders’ deficit table. After quarter-end, NWBO entered a $7 million commercial loan agreement dated May 12, 2026. The loan has no repayments for the first 8 months, payments start January 11, 2027, it has a 10% original issue discount, 8% interest, and a 22-month term. The funds are designated for upcoming capital expenditures and operating expenses. Management / business progress Management says NWBO remains focused on personalized immune therapies for cancer using the DCVax platform. Its lead product remains DCVax-L for solid tumors where the tumor can be surgically removed, especially GBM. The filing says the 331-patient international Phase III DCVax-L trial has been completed, results were published in JAMA Oncology, and the UK MAA was submitted on December 20, 2023. For the UK MAA, management says much of the company’s time and resources in Q1 were devoted to active engagement in the review process. Importantly, NWBO repeats that it does not plan interim announcements while the MAA is going through the regulatory process and plans to announce results when the review and decision-making are finished. NWBO also highlighted Dr. Annalisa Jenkins as a new UK strategic advisor, stating she has big pharma, biotech, and medical innovation experience and will help advance the DCVax cancer vaccine platform. On manufacturing and commercialization prep, management disclosed several items: the London Welbeck Hospital leukapheresis clinic buildout was underway, with two leukapheresis units capable of four patients per day; the Sawston Grade C lab work continued but physical construction was paused while engineering work continued; NWBO continued exploring a second UK production operation; and it entered a U.S. technology-transfer agreement for DCVax-L manufacturing capacity, with engineering runs and validations anticipated during the summer. NWBO also disclosed progress on in-licensed technologies: an updated trial design and IND package for an initial Kalinski/aDC1 clinical trial were completed, submitted to the IRB at the lead institution, and the company anticipated FDA submission in Q2 2026. Legal proceedings The main legal proceeding is the market-maker lawsuit in SDNY. NWBO says it originally filed the complaint on December 1, 2022, alleging certain market makers manipulated NWBO’s stock in violation of the Exchange Act and common-law fraud. The amended complaint named Canaccord Genuity, Citadel Securities, G1 Execution Services, GTS Securities, Instinet, Lime Trading, and Virtu Americas. The case has survived key dismissal stages in part. The filing says the magistrate judge found NWBO had adequately pled all elements of market manipulation except enough detail on loss causation/damages, and later proceedings led to a second amended complaint and discovery. The parties are now in fact discovery, the current fact discovery deadline is August 28, 2026, and no trial date has been set. New disclosure: on April 30, 2026, NWBO and one lesser defendant agreed to resolve NWBO’s case against that defendant by confidential settlement. NWBO says the funds are being held in escrow while it pursues discussions with other lesser defendants, and it expects funds to be released when those discussions are completed. Separately, the P&L includes a $2.25 million gain related to the Delaware litigation settlement during Q1 2026. That appears separate from the SDNY market-maker case and helped reduce the reported net loss.

$NWBO Mark this down. This company and its string of successes and bio technology will create one of the biggest (top 5) short squeezes in stock market history. It’s bottled up.